Q32 Bio Inc
QTTB2.430USD
+0.170+7.52%
收盤 11/10, 16:00（美東）報價延遲15分鐘
29.64M總市值
虧損本益比TTM
關於 Q32 Bio Inc 公司
Q32 Bio Inc. 是一家臨牀階段的生物技術公司。該公司致力於開發針對先天和適應性免疫系統強效調節劑的生物療法，以重新平衡自身免疫和炎症疾病中的免疫力。其主要項目專注於 IL-7/TSLP 受體途徑和補體系統，解決免疫失調問題，幫助患者重新掌控自己的生活。其適應性免疫項目 bempikibart (ADX-914) 是一種完全人源抗 IL-7Ra 抗體，可重新調節適應性免疫功能，用於治療自身免疫性疾病。它正在兩項 II 期試驗中進行評估，用於治療特應性皮炎和斑禿。其先天免疫項目 ADX-097 基於一個平臺，該平臺能夠對補體系統進行組織靶向調節，而無需長期全身阻斷。該公司已在健康志願者中完成了 ADX-097 的首次人體 I 期遞增劑量臨牀研究。
Q32 Bio Inc簡介
公司代碼QTTB
公司名稱Q32 Bio Inc
上市日期Mar 28, 2018
CEOMs. Jodie Pope Morrison
員工數量42
證券類型Ordinary Share
年結日Mar 28
公司地址830 Winter Street
城市WALTHAM
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02451
電話17819990232
網址https://www.q32bio.com/
公司代碼QTTB
上市日期Mar 28, 2018
CEOMs. Jodie Pope Morrison
Q32 Bio Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
收入明細
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
ARCH Venture Partners
2.63%
其他
46.12%
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
ARCH Venture Partners
2.63%
其他
46.12%
股東類型
持股股東
佔比
Venture Capital
28.82%
Private Equity
18.47%
Investment Advisor
17.55%
Corporation
5.92%
Hedge Fund
1.98%
Investment Advisor/Hedge Fund
1.72%
Research Firm
1.17%
Individual Investor
0.62%
其他
23.75%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
197
8.50M
69.71%
-4.30M
2025Q2
211
9.72M
79.73%
-4.89M
2025Q1
223
10.26M
84.16%
-4.38M
2024Q4
223
11.35M
93.20%
-1.04M
2024Q3
208
11.60M
102.62%
+2.77M
2024Q2
197
10.02M
90.20%
+1.83M
2024Q1
230
9.37M
85.14%
+7.24M
2023Q4
242
1.68M
52.16%
-377.72K
2023Q3
262
1.62M
50.50%
-460.61K
2023Q2
275
1.63M
50.84%
-543.11K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
OrbiMed Advisors, LLC
2.25M
18.47%
--
--
Jun 30, 2025
Atlas Venture
2.09M
17.15%
--
--
Jun 30, 2025
Abingworth Management Limited
1.10M
9.04%
--
--
Jun 30, 2025
Acorn Capital Advisors, LLC
803.42K
6.59%
--
--
Jun 30, 2025
ARCH Venture Partners
320.48K
2.63%
--
--
Jun 30, 2025
Monaco asset management S.A.M.
591.94K
4.85%
+86.49K
+17.11%
Jun 30, 2025
The Vanguard Group, Inc.
269.43K
2.21%
-39.78K
-12.87%
Jun 30, 2025
Pfizer Inc
277.78K
2.28%
--
--
Jun 30, 2025
Sanofi SA
244.08K
2%
--
--
Jun 30, 2025
Bristol Myers Squibb
200.24K
1.64%
-558.90K
-73.62%
Dec 31, 2024
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Hypatia Women CEO ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Goldman Sachs Innovate Equity ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
查看更多
Fidelity Enhanced Small Cap ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Hypatia Women CEO ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
Goldman Sachs Innovate Equity ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
公告日期
類型
比率
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
